Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laszlo Endrenyi

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|April 25, 2013
Approvable generic carbamazepine formulations may not be bioequivalent in target patient populationsLaszlo Tothfalusi, Laszlo Endrenyi
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|February 28, 2012
Sample sizes for designing bioequivalence studies for highly variable drugsLaszlo Tothfalusi, Laszlo Endrenyi
Pharmaceutical Research|April 3, 2003
Limits for the scaled average bioequivalence of highly variable drugs and drug productsLaszlo Tothfalusi, Laszlo Endrenyi
Omics : a Journal of Integrative Biology|December 11, 2020
Rethinking Clinical Trials and Personalized Medicine with Placebogenomics and Placebo DoseVural Özdemir, Laszlo Endrenyi
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|May 12, 2010
Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products?Laszlo Endrenyi, Laszlo Tothfalusi
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|January 8, 2014
Determination of bioequivalence for drugs with narrow therapeutic index: reduction of the regulatory burdenLaszlo Endrenyi, Laszlo Tothfalusi
Journal of Biopharmaceutical Statistics|April 27, 2019
Interchangeability Of Biological Drug Products-FDA Draft GuidanceLaszlo Endrenyi, Richard Markus
The AAPS Journal|February 3, 2016
An Exact Procedure for the Evaluation of Reference-Scaled Average BioequivalenceLaszlo Tothfalusi, Laszlo Endrenyi
Statistics in Medicine|August 30, 2017
Algorithms for evaluating reference scaled average bioequivalence: power, bias, and consumer riskLaszlo Tothfalusi, Laszlo Endrenyi
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
Estimation of Cmax and Tmax in populations after single and multiple drug administrationsLaszlo Tothfalusi, Laszlo Endrenyi
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
International Journal of Clinical Pharmacology and Therapeutics|April 25, 2013
Approvable generic carbamazepine formulations may not be bioequivalent in target patient populationsLaszlo Tothfalusi, Laszlo Endrenyi
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|February 28, 2012
Sample sizes for designing bioequivalence studies for highly variable drugsLaszlo Tothfalusi, Laszlo Endrenyi
Pharmaceutical Research|April 3, 2003
Limits for the scaled average bioequivalence of highly variable drugs and drug productsLaszlo Tothfalusi, Laszlo Endrenyi
Omics : a Journal of Integrative Biology|December 11, 2020
Rethinking Clinical Trials and Personalized Medicine with Placebogenomics and Placebo DoseVural Özdemir, Laszlo Endrenyi
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|May 12, 2010
Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products?Laszlo Endrenyi, Laszlo Tothfalusi
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|January 8, 2014
Determination of bioequivalence for drugs with narrow therapeutic index: reduction of the regulatory burdenLaszlo Endrenyi, Laszlo Tothfalusi
Journal of Biopharmaceutical Statistics|April 27, 2019
Interchangeability Of Biological Drug Products-FDA Draft GuidanceLaszlo Endrenyi, Richard Markus
The AAPS Journal|February 3, 2016
An Exact Procedure for the Evaluation of Reference-Scaled Average BioequivalenceLaszlo Tothfalusi, Laszlo Endrenyi
Statistics in Medicine|August 30, 2017
Algorithms for evaluating reference scaled average bioequivalence: power, bias, and consumer riskLaszlo Tothfalusi, Laszlo Endrenyi
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
Estimation of Cmax and Tmax in populations after single and multiple drug administrationsLaszlo Tothfalusi, Laszlo Endrenyi
Pageof 4